Radiology Unit, Department of Diagnostic Medicine and Prevention, Sant'Orsola Hospital, University of Bologna, Bologna, Italy.
Department of Medical and Surgical Sciences, Sant'Orsola Hospital, University of Bologna, Bologna, Italy.
Gut. 2018 Sep;67(9):1674-1682. doi: 10.1136/gutjnl-2017-315384. Epub 2018 Feb 3.
Many improvements have been made in diagnosing hepatocellular carcinoma (HCC), but the radiological hallmarks of HCC have remained the same for many years. We prospectively evaluated the imaging criteria of HCC, early HCC and high-grade dysplastic nodules (HGDNs) in patients under surveillance for chronic liver disease, using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) MRI and diffusion-weighted imaging.
Our study population included 420 nodules >1 cm in 228 patients. The MRI findings of each nodule were collected in all sequences/phases. The diagnosis of HCC was made according to the American Association for the Study of Liver Diseases (AASLD) criteria; all atypical nodules were diagnosed using histology.
A classification and regression tree was developed using three MRI findings which were independently significant correlated variables for early HCC/HCC, and the best sequence of their application in a new diagnostic algorithm (hepatobiliary hypointensity, arterial hyperintensity and diffusion restriction) was suggested. This algorithm demonstrated, both in the entire study population and for nodules ≤2 cm, higher sensitivity (96% [95% CI 93.5% to 97.6%] and 96.6% [95% CI 93.9% to 98.5%], P<0.001, respectively) and slightly lower specificity (91.8% [95% CI 88.6% to 94.1%], P=0.063, and 92.7% [95% CI 88.9% to 95.4%], P=0.125, respectively) than those of the AASLD criteria. Our new diagnostic algorithm also showed a very high sensitivity (94.7%; 95% CI 92% to 96.6%) and specificity (99.3%; 95% CI 97.7% to 99.8%) in classifying HGDN.
Our new diagnostic algorithm demonstrated significantly higher sensitivity and comparable specificity than those of the AASLD imaging criteria for HCC in patients with cirrhosis evaluated using Gd-EOB-DTPA MRI, even for lesions ≤2 cm. Moreover, this diagnostic algorithm allowed evaluating other lesions which could arise in a cirrhotic liver, such as early HCC and HGDN.
肝细胞癌(HCC)的诊断已有诸多改进,但 HCC 的影像学特征多年来一直没有变化。我们前瞻性地评估了在慢性肝病监测患者中,使用钆塞酸二钠(Gd-EOB-DTPA)MRI 和弥散加权成像的 HCC、早期 HCC 和高级别异型增生结节(HGDN)的影像学标准。
我们的研究人群包括 228 名患者中的 420 个>1cm 的结节。收集了所有序列/相位中每个结节的 MRI 发现。根据美国肝病研究协会(AASLD)标准诊断 HCC;所有非典型结节均采用组织学诊断。
使用三个与早期 HCC/HCC 独立相关的 MRI 发现建立了分类回归树,提出了最佳序列(肝胆期低信号、动脉期高信号和弥散受限)及其在新诊断算法中的应用顺序。该算法在整个研究人群和≤2cm 的结节中显示出更高的灵敏度(96%[95%CI 93.5%至 97.6%]和 96.6%[95%CI 93.9%至 98.5%],P<0.001)和稍低的特异性(91.8%[95%CI 88.6%至 94.1%],P=0.063 和 92.7%[95%CI 88.9%至 95.4%],P=0.125),优于 AASLD 标准。我们的新诊断算法在诊断 HGDN 时也具有非常高的灵敏度(94.7%;95%CI 92%至 96.6%)和特异性(99.3%;95%CI 97.7%至 99.8%)。
在使用 Gd-EOB-DTPA MRI 评估肝硬化患者时,我们的新诊断算法对 HCC 的灵敏度显著高于 AASLD 成像标准,特异性也相当,甚至对≤2cm 的病变也是如此。此外,该诊断算法还可以评估肝硬化肝脏中可能出现的其他病变,如早期 HCC 和 HGDN。